An electron microscopic (EM) image shows mature, oval-shaped monkeypox virus particles as well as crescents and spherical particles of immature virions, obtained from a clinical human skin sample associated with the 2003 prairie dog outbreak in this undated image obtained by Reuters on May 18, 2022. Cynthia S. Goldsmith, Russell Regnery/CDC/Handout via REUTERS
Bavarian Nordic, a Danish biotechnology firm, said on Monday that the European Commission has granted clearance for its Imvanex vaccine to be sold as protection against monkeypox, as recommended by the European Medicines Agency last week (EMA).
The decision comes only one day after the World Health Organization declared the quickly growing monkeypox outbreak a global health emergency.
Bavarian’s vaccine, the only one to have won approval for the prevention of monkeypox disease in the United States and Canada, has in the EU so far only been approved to treat smallpox.
